Emerging drugs for overactive bladder

Bibliography

• Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167–78
   PubMed Web of Science ®Google Scholar
• Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006;175:191–4
   PubMed Web of Science ®Google Scholar
• Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;108(7):1132–8
   PubMed Web of Science ®Google Scholar
• Wagner TH, Hu TW, Bentkover J, et al. Health-related consequences of overactive bladder. Am J Manag Care 2002;8(Suppl):S598–607
   Google Scholar
• Irwin DE, Mungapen L, Milsom I, et al. The economic impact of overactive bladder syndrome in six western countries. BJU Int 2008;103:202–9
   Web of Science ®Google Scholar
• Thuroff J, Abrams P, Andersson KE, et al. EAU guidelines on urinary incontinence. Eur Urol 2011;59:387–400
   PubMed Web of Science ®Google Scholar
• Swithinbank L, Hashim H, Abrams P. The effect of fluid intake on urinary symptoms in women. J Urol 2005;174(1):187–9
   PubMed Web of Science ®Google Scholar
• Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstet Gynecol 2000;96(1):85–9
   PubMed Web of Science ®Google Scholar
• Dumoulin C, Hunter KF, Moore K, et al. Conservative management for female urinary incontinence and pelvic organ prolapse review 2013: Summary of the 5th international consultation on incontinence. Neurourol Urodyn 2014. [Epub ahead of print]
   Google Scholar
• Editors National Collaborating Centre for Women’s and Children’s Health [UK]. Urinary Incontinence in Women: The Management of Urinary Incontinence in Women. Source London: Royal College of Obstetricians and Gynaecologists [UK]; 2013 Sep. National Institute for Health and Clinical Excellence: Guidance
   Google Scholar
• Groen J, Blok BF, Bosch JL. Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. J Urol 2011;186(3):954–9
   PubMed Web of Science ®Google Scholar
• Peters KM, Carrico DJ, Wooldridge LS, et al. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol 2013;189(6):2194–201
   PubMed Web of Science ®Google Scholar
• Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006(4):CD003781
   Google Scholar
• Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3(1):46–53
   PubMed Web of Science ®Google Scholar
• Harvey M, Baker K, Wells G. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 2001;185(1):56–61
   PubMed Web of Science ®Google Scholar
• Chapple C, Araño P, Bosch J. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004;93(1):71–7
   PubMed Web of Science ®Google Scholar
• Herschorn S, Swift S, Guan Z. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2010;105(1):58–66
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Davila GW, Zinner NR, et al. Efficacy and Safety of Transdermal Oxybutynin in Patients With Urge and Mixed Urinary Incontinence. J Urol 2002;168(2):580–6
   PubMed Web of Science ®Google Scholar
• Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010;64(9):1294–300
   PubMed Web of Science ®Google Scholar
• Pagoria D, O’Connor R, Guralnick M. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep 2011;12(5):351–7
   PubMedGoogle Scholar
• Leone Roberti Maggiore U, Scala C, Venturini PL, et al. Imidafenacin for the treatment of overactive bladder. Expert Opin Pharmacother 2013;14(10):1383–97
   PubMed Web of Science ®Google Scholar
• Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003;170(2 Pt 1):649–53
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β[3]-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63(2):283–95
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol 2014;21(10):960–7
   PubMed Web of Science ®Google Scholar
• Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov 2014;9(4):433–48
   PubMed Web of Science ®Google Scholar
• Aballéa S, Maman K, Thokagevistk K, et al. Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom. Clin Drug Investig 2014; Epub ahead of print
   Web of Science ®Google Scholar
• Chapple C, Khullar V, Nitti VW, et al. Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials. Eur Urol 2015;67(1):11–14
   PubMed Web of Science ®Google Scholar
• Calmasini FB, Candido TZ, Alexandre EC, et al. The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?. Prostate 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Lose G, Matiasson A, Walter S, et al. Clinical experiences with desmopressin for long term treatment of nocturia. J Urol 2004;172(3):1021–5
   PubMed Web of Science ®Google Scholar
• Rembratt A, Norgaard JP, Andersson K. Desmopressin in elderly patients with nocturia: short-term safety and effects on urine output, sleep and voiding patterns. BJU Int 2003;91(7):642–6
   PubMed Web of Science ®Google Scholar
• Simunić V, Banović I, Ciglar S, et al. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 2003;82(2):187–97
   PubMed Web of Science ®Google Scholar
• Tincello DG, Kenyon S, Abrams KR, et al. Botulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women [the RELAX study]. Eur Urol 2012;62(3):507–14
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010;184(6):2416–22
   PubMed Web of Science ®Google Scholar
• Malde S, Dowson C, Fraser O, et al. Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder. BJU Int 2014; Epub ahead of print
   Web of Science ®Google Scholar
• Kuo HC. Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions. J Urol 2003;170(3):835–9
   PubMed Web of Science ®Google Scholar
• Birder LA, de Groat WC. Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol 2007;4(1):46–54
   PubMedGoogle Scholar
• Birder LA. Nervous network for lower urinary tract function. Int J Urol 2013;20(1):4–12
   PubMed Web of Science ®Google Scholar
• Deruyver Y, Voets T, De Ridder D, et al. Transient receptor potential channel modulators as pharmacological treatments for lower urinary tract symptoms: myth or reality? BJU Int 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Tonini M, Messori E, Franceschetti GP, et al. Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. Br J Pharmacol 1994;113(1):1–2
   PubMed Web of Science ®Google Scholar
• Takagi-Matsumoto H, Ng B, Tsukimi Y, Tajimi M. Effects of NSAIDs on bladder function in normal and cystitis rats: a comparison study of aspirin, indomethacin, and ketoprofen. J Pharmacol Sci 2004;95(4):458–65
   PubMed Web of Science ®Google Scholar
• Petkov GV. Role of potassium ion channels in detrusor smooth muscle function and dysfunction. Nat Rev Urol 2011;9(1):30–40
   PubMed Web of Science ®Google Scholar
• Sacco E, Pinto F, Bassi P. Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. Int Urogynecol J Pelvic Floor Dysfunct 2008;19(4):583–98
   PubMed Web of Science ®Google Scholar
• Shiomi H, Takahashi N, Kawashima Y, et al. Involvement of stretch-induced Rho-kinase activation in the generation of bladder tone. Neurourol Urodyn 2013;32(7):1019–25
   PubMed Web of Science ®Google Scholar
• Salcedo C, Balsa D, Enrich A, et al. SVT-40776, A new selective M3 muscarinic antagonist: Human receptor binding profile and bladder effects in the guinea pig. ICS 2003;13
   Google Scholar
• Viayna C, Alvarez D, López R, et al. A randomised, placebo-controlled, dose-rising study in healthy males volunteers to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of SVT-40776, a novel selective M3 antimuscarinic. ICS/IUGA 2004;270
   Google Scholar
• Song M, Kim JH, Lee KS, et al. The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study. Int J Clin Pract 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• SALVAT and kwang dong announced positive results of Phase IIb for tarafenacin. 2013. Available from: www.salvatbiotech.com/en/noticias/salvat-and-kwang-dong-announced-positive-results-of-phase-iib-for-tarafenacin
   Google Scholar
• Gittelman M, Weiss H, Seidman L. A Phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. J Urol 2014;191(4):1014–21
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher C, Staskin D et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study [symphony]. A J Urol Suppl 189(4S):e803
   Google Scholar
• Kaplan S, He W, Koltun W, et al. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol 2013;63(1):158–65
   PubMed Web of Science ®Google Scholar
• Han Y, Lee W, Lee S, et al. Effect of desmopressin with anticholinergics in female patients with overactive bladder. Korean J Urol 2011;52(6):396–400
   PubMedGoogle Scholar
• Yamamoto S, Yamamoto T, Yamaguchi N, et al. SMP-986, a Na+-channel blocker and a muscarinic receptor antagonist, showed increased voiding efficiency in anesthetized dogs. ICS 2006;254
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00409539
   Google Scholar
• Dmochowski RR, Staskin DR, Duchin K, et al. Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder. Int J Clin Pract 2014;68(8):986–94
   PubMed Web of Science ®Google Scholar
• Flugel R, Paborji M, Duchin K, et al. Dose escalation of a muscarinic antagonist with THVD-201, a novel combination drug product containing tolterodine and pilocarpine [a muscarinic agonist and salivary stimulant]. ICS 2013;293
   Google Scholar
• Ohlstein E, von Keitz A, Michel MA. Multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 2012;62(5):834–40
   PubMed Web of Science ®Google Scholar
• Maruyama I, Goi Y, Tatemichi S, et al. Bladder selectivity of the novel β 3-agonist ritobegron [KUC-7483] explored by in vitro and in vivo studies in the rat. Naunyn-Schmiedeberg’s Arch Pharmacol 2012;385(8):845–52
   Google Scholar
• Chuang Y, Tyagi P, Huang C, et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin a delivery using liposomes. J Urol 2009;182(2):786–92
   PubMed Web of Science ®Google Scholar
• Kuo H, Liu T, Chuang Y, et al. Pilot study of liposome-encapsulated onabotulinumtoxinA for patients with overactive bladder: a single-center study. Eur Urol 2014;65(6):1117–24
   PubMed Web of Science ®Google Scholar
• Chuang Y, Kaufmann J, Chancellor D, et al. Bladder instillation of liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. J Urol 2014;192(6):1743–9
   PubMed Web of Science ®Google Scholar
• Keith F, John C. Targeted secretion inhibitors-innovative protein therapeutics. Toxins [Basel] 2010;2(12):2795–815
   PubMed Web of Science ®Google Scholar
• Nilius B, Owsianik G, Voets T, et al. Transient receptor potential cation channels in disease. Physiol Rev 2007;87(1):165–217
   PubMed Web of Science ®Google Scholar
• Hristov K, Parajuli S, Smith A, et al. MP17-05 Potential novel target for treatment of overactive bladder: Transient receptor potential melastatin 4 channel in human urinary bladder. J Urol 2014;191(4):e136–7
   Google Scholar
• Merrill L, Vizzard MA. Intravesical TRPV4 blockade reduces repeated variate stress-induced bladder dysfunction by increasing bladder capacity and decreasing voiding frequency in male rats. Am J Physiol Regul Integr Comp Physiol 2014;307(4):R471–80
   PubMed Web of Science ®Google Scholar
• Almeida MC, Hew-Butler T, Soriano RN, et al. Pharmacological blockade of the cold receptor TRPM8 attenuates autonomic and behavioral cold defenses and decreases deep body temperature. J Neurosci 2012;32(6):2086–99
   PubMed Web of Science ®Google Scholar
• Haab F, Braticevici B, Krivoborodov G, et al. Efficacy and safety of repeated dosing of netupitant, a neurokinin-1 receptor antagonist. in treating overactive bladder Neurourol Urodynamics 2014;33(3):335–40
   PubMed Web of Science ®Google Scholar
• Frenkl TL, Zhu H, Reiss T, et al. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol 2010;184(2):616–22
   PubMed Web of Science ®Google Scholar
• Zát’ura F, Všetiča J, Abadías M, et al. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Eur Urol 2010;57(1):145–52
   PubMed Web of Science ®Google Scholar
• Cardozo L, Stanton S, Robinson H, et al. Evaluation of flurbiprofen in detrusor instability. Br Med J 1980;280(6210):281
   PubMed Web of Science ®Google Scholar
• Rufford J, Cardozo L, Toozs-Hobson P, et al. HCT 1026–a novel treatment for urgency? 32nd Annual Meeting of the International Continence Society. Heidelberg, Germany, 2002. p. 225
   Google Scholar
• Sprem M, Milicić D, Oresković S, et al. Intravesically administered ketoprofen in treatment of detrusor instability: cross-over study. Croatian Med J 2000;41(4):423–7
   PubMed Web of Science ®Google Scholar
• Chapple CR, Abrams P, Andersson KE, et al. Phase II Study on the Efficacy and Safety of the EP1 Receptor Antagonist ONO-8539 for Nonneurogenic Overactive Bladder Syndrome. J Urol 2014;191(1):253–60
   PubMed Web of Science ®Google Scholar
• Atobe M, Naganuma K, Kawanishi M, et al. Discovery of 2-[1H-indazol-1-yl]-thiazole derivatives as selective EP1 receptor antagonists for treatment of overactive bladder by core structure replacement. Bioorganic Med Chem Letters 2014;24(5):1327–33
   PubMed Web of Science ®Google Scholar
• Tonini M, Messori E, Franceschetti GP, et al. Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. Br J Pharmacol 1994;113(1):1–2
   PubMed Web of Science ®Google Scholar
• Steers WD, Herschorn S, Kreder KJ, et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 2007;100(2):337–45
   PubMed Web of Science ®Google Scholar
• Vela Navarrete R, Pérez Martínez F, Castilla Reparaz C, et al. Comparative effects of duloxetine, besipirdine, and clomipramine on striated sphincter activity and bladder function in a rabbit model. Abstract number UP-03.85. Urology 2006;68:310–11
   Google Scholar
• Niimi A, Nomiya A, Nishimatsu H, et al. The Use of Tramadol for Refractory Interstitial Cystitis: Retrospective Analysis of Fifteen Cases. Int J Urol 21(S1):PO–17
   Google Scholar
• Fujimura M, Izumimoto N, Momen S, et al. Characteristics of TRK-130 [Naltalimide], a novel opioid ligand, as a new therapeutic agent for overactive bladder. J Clin Neuropharmacol 2006;29(4):206–14
   PubMed Web of Science ®Google Scholar
• Carbone A, Palleschi G, Conte A, et al. Gabapentin treatment of neurogenic overactive bladder. Inghilleri M.pharmacol Exp Therap 2014;350(3):543–51
   PubMed Web of Science ®Google Scholar
• Kim YT, Kwon DD, Kim J, et al. Gabapentin for overactive bladder and nocturia after anticholinergic failure. Int Braz J Urol 2004;30(4):275–8
   PubMedGoogle Scholar
• Kwon WA, Ahn SH, Oh TH, et al. Effect of low-dose triple therapy using gabapentin, amitriptyline, and a nonsteroidal anti-inflammatory drug for overactive bladder symptoms in patients with bladder pain syndrome. Int Neurourol J 2013;17(2):78–82
   PubMed Web of Science ®Google Scholar
• Marencak J, Cossons NH, Darekar A, et al. Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder. Neurourol Urodyn 2011;30(1):75–82
   PubMed Web of Science ®Google Scholar
• Loutochin O, Afraa T, Campeau L, et al. Effect of the anticonvulsant medications Pregabalin and Lamotrigine on urodynamic parameters in an animal model of neurogenic detrusor overactivity. Neurourol Urodynamics 2012;31(7):1197–202
   PubMed Web of Science ®Google Scholar
• Tyagi V, Philips B, Su R, et al. Differential Expression of Functional Cannabinoid Receptors in Human Bladder Detrusor and Urothelium. J Urol 2009;181(4):1932–8
   PubMed Web of Science ®Google Scholar
• Hiragata S, Ogawa T, Hayashi Y, et al. Effects of IP-751, ajulemic acid, on bladder. overactivity induced by bladder irritation in rats Naoki. Urology 2007;70(1):202–8
   PubMed Web of Science ®Google Scholar
• Freeman R, Adekanmi O, Waterfield M, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial [CAMS-LUTS]. Int Urogynecol J 2006;17(6):636–41
   PubMed Web of Science ®Google Scholar
• Schuler V, Suter K, Fürer K, et al. Bryophyllum pinnatum inhibits detrusor contractility in porcine bladder strips – A pharmacological study towards a new treatment option of overactive bladder. Phytomedicine 2012;19(10):947–51
   PubMed Web of Science ®Google Scholar
• Huang YB, Lin MW, Chao Y, et al. Anti-oxidant activity and attenuation of bladder hyperactivity by the flavonoid compound kaempferol. Int J Urol 2014;21(1):94–8
   PubMed Web of Science ®Google Scholar
• Capasso R, Tavares IA. Effect of the flavonoid galangin on urinary bladder rat contractility in-vitro. J Pharm Pharmacol 2002;54(8):1147–50
   PubMed Web of Science ®Google Scholar
• Melman A, Bar-chama N, Mccullough A, et al. Plasmid-based gene transfer for treatment of erectile dysfunction and overactive bladder: results of a phase I trial. Israel Med Assoc J IMAJ 2007;9(3):143–6
   PubMed Web of Science ®Google Scholar
• Oguchi T, Funahashi Y, Yokoyama H, et al. Effect of herpes simplex virus vector-mediated interleukin-4 gene therapy on bladder overactivity and nociception. Urology 2012;80(1):48–54
   PubMed Web of Science ®Google Scholar
• Miyazato M, Sugaya K, Goins WF, et al. Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats. Gene Ther 2009;16(5):660–8
   PubMed Web of Science ®Google Scholar
• Beckel JM, Kanai A, Lee SJ, et al. Expression of functional nicotinic acetylcholine receptors in rat urinary bladder epithelial cells. Am J Physiol Renal Physiol 2006;290(1):F103–10
   Google Scholar
• Targacept to discontinue TC-5214 overactive bladder program. 2014. Available from: www.targacept.com/newsroom/index.cfm?nid=Targacept%20to%20Discontinue%20TC-5214%20Overactive%20Bladder%20Program&newsyear=2014
   Google Scholar
• La Fuente J, Fernández A, Cuevas P, et al. Stimulation of large-conductance calcium-activated potassium channels inhibits neurogenic contraction of human bladder from patients with urinary symptoms and reverses acetic acid-induced bladder hyperactivity in rats. Eur J Pharmacol 2014;735:68–76
   PubMed Web of Science ®Google Scholar
• Chapple CR, Patroneva A, Raines SR. Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study [ZD0947IL/0004]. Eur Urol 2006;49(5):879–86
   PubMed Web of Science ®Google Scholar
• Michel MC, Radziszewski P, Falconer C, et al. Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. Br J Clin Pharmacol 2012;73(5):821–5
   PubMed Web of Science ®Google Scholar
• Martínez-salamanca J, Carballido J, Eardley I, et al. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. Eur Urol 2011;60(3):527–35
   PubMed Web of Science ®Google Scholar
• Drake MJ. Emerging drugs for treatment of overactive bladder and detrusor overactivity. Expert Opin Emerg Drugs 2008;13(3):431–46
   PubMed Web of Science ®Google Scholar
• Digesu GA, Verdi E, Cardozo L, et al. Phase IIb, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine effects of elocalcitol in women with overactive bladder and idiopathic detrusor overactivity. Colli Enrico Urol 2012;80(1):48–54
   Web of Science ®Google Scholar